Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Blood (2019) 134 (Supplement_1): 695.

https://doi.org/10.1182/blood-2019-121694

Published: 2019

Journal Articles

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Melissa Castiglione, BS, Christopher Mazzeo, BS, Ya-Ping Jiang, Juei-Suei Chen, Wei Yin, Richard Lin, Huichun Zhan, MD

Blood (2019) 134 (Supplement_1): 7.

https://doi.org/10.1182/blood-2019-131372

Published: 2019

Journal Articles

Cardiac Injury and Microvascular Ischemia in Sickle Cell Disease

Kiranveer Kaur, Ying Huang, MS, MA, Subha Raman, MD MS, Eric H. Kraut, MD, Payal Desai, MD

Blood (2019) 134 (Supplement_1): 2286.

https://doi.org/10.1182/blood-2019-125445

Published: 2019

Journal Articles

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

Siavash Piran, MDMSc,FRCPC, Michelle Zondag, BSN, RN, Drew Bednar, MD FRCSC, Brian Drew, MD FRCSC, Agnes Chmiel, MD FRCPC, Noel Chan, MBBS, MRCP, FRACP, FRCPA, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Sam Schulman, MD PhD FRCPC

Blood (2019) 134 (Supplement_1): 2434.

https://doi.org/10.1182/blood-2019-124601

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

Journal Articles

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Blood (2019) 134 (Supplement_1): 353.

https://doi.org/10.1182/blood-2019-129835

Published: 2019

Journal Articles

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Marco Basset, MD, Paolo Milani, MD PhD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 3312.

https://doi.org/10.1182/blood-2019-130364

Published: 2019

Journal Articles

Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Thomas Alexander, MD MPH, Norman J. Lacayo, MD, Vinod A. Pullarkat, MD, Elias J. Jabbour, MD, Seong Lin Khaw, MD, Charles G. Mullighan, MBBS, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Jessica Leonard, MD, Robin Norris, MD, Jeffrey Rubnitz, MD PhD, Susan I. Vear, MD MSCI, Michelle Schmidt, Bo Tong, PhD, Ying Zhou, PhD, Jeremy A. Ross, PhD, Lindsey Rosenwinkel, Amanda Jacobson, PhD, Su Young Kim, MD PhD, Wendy Stock, MD

Blood (2018) 132 (Supplement 1): 3966.

https://doi.org/10.1182/blood-2018-99-113464

Published: 2018

Journal Articles

Leukemia Risk Gene ARID5B is a Crucial Regulator of B-Cell Development

Charnise Goodings-Harris, PhD, Hui Zhang, PhD, Xuijie Zhao, Heng Xu, PhD, Omar I Abdel-Wahab, MD, Shannon McKinney-Freeman, PhD, Jun J. Yang, PhD

Blood (2018) 132 (Supplement 1): 385.

https://doi.org/10.1182/blood-2018-99-113686

Published: 2018

Journal Articles

Hydroxyurea Therapy Does Not Impact Current Survival Estimates in the East London Sickle Cell Newborn Cohort Study

Paul Telfer, Banu Kaya, MD, Dimitris A. Tsitsikas, Filipa Barroso, MD, Cynthia Sangarappillai, BSc

Blood (2018) 132 (Supplement 1): 3655.

https://doi.org/10.1182/blood-2018-99-116544

Published: 2018

Journal Articles

Real World Experience with Sublingual Fentanyl for the Treatment of Sickle Cell Vaso-Occlusive Episodes in Adults in a Tertiary Canadian Emergency Department

Hayley Merkeley, MD, Sam Sabbah, MBBS, MSc, Richard Ward, MBBS, MRCP, Kevin H. M. Kuo, MD MSc,FRCPC

Blood (2018) 132 (Supplement 1): 5879.

https://doi.org/10.1182/blood-2018-99-116676

Published: 2018

Journal Articles

Sudden Death in Sickle Cell Disease: An Assessment of Risk Factors

Chijioke Nze, MD, Brooke M Fortin, BA, BS, Revital Freedman, PhD, Maneka Puligandla, MS, Donna S Neuberg, ScD, Elyse Mandell, ANP, Maureen Achebe, MD MPH

Blood (2018) 132 (Supplement 1): 4929.

https://doi.org/10.1182/blood-2018-99-119860

Published: 2018

Journal Articles

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study

Blood (2018) 132 (Supplement 1): 3147.

https://doi.org/10.1182/blood-2018-99-118280

Published: 2018

Journal Articles

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Paolo Strati, MD, Koichi Takahashi, MD, Michael J. Keating, MD, Philip A. Thompson, MBBS, Christina Hinojosa, Diana Rodriguez, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, William G. Wierda, MD PhD, Andrew Futreal, PhD, Alessandra Ferrajoli, MD

Blood (2018) 132 (Supplement 1): 295.

https://doi.org/10.1182/blood-2018-99-111488

Published: 2018

Journal Articles

Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study

Merav Barzilai, MD, Ilya Kirgner, MD, Martin Ellis, MD, Irit Avivi, MD, Najib Dally, MD, Uri Rozovski, Noa Lavi, MD

Blood (2017) 130 (Supplement 1): 2917.

https://doi.org/10.1182/blood.V130.Suppl_1.2917.2917

Published: 2017

Journal Articles

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Elisabeth Schorb, MD, Chris P Fox, Benjamin Kasenda, MDPhD, Teresa Calimeri, MDPhD, Kim Linton, MBChB PhD, Jeffery Smith, MBChB BMedSci MRCP FRCPath, Slavisa Ninkovic, MBBS FRACP FRCPA, Deborah Yallop, MBBS FRCP FRCPath PhD, Hans-Guido Holl, MD, Alberto Fabbri, MD, Thomas E C Cummin, MRCP MBBCh BSc, Gerald Illerhaus, MD, Kate Cwynarski, PhDMD, Andrés J M Ferreri, MD

Blood (2017) 130 (Supplement 1): 376.

https://doi.org/10.1182/blood.V130.Suppl_1.376.376

Published: 2017

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Anas Younes, MD, Burke M. John, Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, Jeffrey P. Sharman, MD, Monica Tani, Chaitra S. Ujjani, MD, Umberto Vitolo, MD, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, Michael Gilbertson

Blood (2017) 130 (Supplement 1): 481.

https://doi.org/10.1182/blood.V130.Suppl_1.481.481

Published: 2017

Journal Articles

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies

Raoul Tibes, MD PhD, Heidi Elizabeth Kosiorek, MS, Amylou Dueck, PhD, Jeanne Palmer, MD, James L. Slack, MD, Emily Ann Knight, NP, Saman Khalid Hashmi, MD, James M. Bogenberger, PhD, Darci Zblewski, CNP, William J. Hogan, MBBCh, Mark R. Litzow, MD, Ruben A Mesa, MD, James M. Foran, MD, Lisa Sproat, MD MSW, Aref Al-Kali, MD

Blood (2017) 130 (Supplement 1): 2629.

https://doi.org/10.1182/blood.V130.Suppl_1.2629.2629

Published: 2017

Journal Articles

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

Jeffrey A Zonder, MD, Vaishali Sanchorawala, MD, Vishal Kukreti, MD FRCP(C), Sascha A Tuchman, MD, Yubin Kang, MD, Divaya Bhutani, MD, Steven Burt, ANP, Christiane Houde, BS, Kathy A. Reichel, Silva Pregja, MBA, Jeffrey V Matous, MD

Blood (2017) 130 (Supplement 1): 3158.

https://doi.org/10.1182/blood.V130.Suppl_1.3158.3158

Published: 2017

Journal Articles

A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

Enrique M. Ocio, MDPhD, Sara Bringhen, MD, Stefania Oliva, MD, Paula Rodriguez-Otero, MD PhD, Dheepak Kanagavel, MD PhD, Corina Oprea, MD, Vivian Wei, Severine Doroumian, Joaquin Martinez-Lopez, MD PhD

Blood (2017) 130 (Supplement 1): 3160.

https://doi.org/10.1182/blood.V130.Suppl_1.3160.3160

Published: 2017

NARROW

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

JAK2V617F-Mediated Endothelial Dysfunction Promotes Congestive Heart Failure in a Murine Model of Myeloproliferative Neoplasm

Cardiac Injury and Microvascular Ischemia in Sickle Cell Disease

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Leukemia Risk Gene ARID5B is a Crucial Regulator of B-Cell Development

Hydroxyurea Therapy Does Not Impact Current Survival Estimates in the East London Sickle Cell Newborn Cohort Study

Real World Experience with Sublingual Fentanyl for the Treatment of Sickle Cell Vaso-Occlusive Episodes in Adults in a Tertiary Canadian Emergency Department

Sudden Death in Sickle Cell Disease: An Assessment of Risk Factors

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only